Stergios Kechagias
Professor
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Professor Stergios Kechagias is a faculty member at Linköpings universitet in Sweden. His research focuses on liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and primary sclerosing cholangitis. Recent contributions to the field include studies on dietary habits and vitamin intake in liver disease patients, as well as the implications of genetic variants and non-invasive diagnostic methods for liver fibrosis. Professor Kechagias's work aims to enhance understanding of liver health and develop effective screening and management strategies.
Articles (16)
Year:
2025
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Aims To investigate the diagnostic accuracy of fecal calprotectin (FC) for inflammatory bowel disease (IBD) and organic gastrointestinal disease (OGID) in primary care. To examine the association with demographic factors, symptoms and concomitant medical therapy. Methods A retrospective analysis of data on all semiquantitative FC tests from individuals ≥18 years conducted in primary care in Östergötland County in 2010. A 5‐year follow‐up with inclusion of new gastrointestinal diagnoses. Results A total of 1293 eligible patients were included. IBD was found in 8.8% and other OGID in 30.8% of patients with positive FC. Positive FC was associated with diarrhea, age >60 years, duration <3 months, use of nonsteroidal anti‐inflammatory drug (NSAID), and proton pump inhibitor (PPI). Predictors of IBD were positive FC, diarrhea, rectal bleeding, and male sex; predictors of OGID positive FC, age >35 years, abnormal clinical findings, and duration <3 months. FC yielded the highest sensitivity and negative predictive value compared with demographic factors, symptoms, and duration. Use of NSAID and PPI showed a marginal increase in the sensitivity, positive predictive value, and decrease in the specificity of FC. Within 5 years, 4.0% had a new gastrointestinal diagnosis among patients with positive FC (0.6% IBD). Conclusions FC reliably rules out IBD and contradicts the presence of other OGID in primary care patients. Positive FC test together with other predictors, such as diarrhea, rectal bleeding, short duration, or age >35 years, should encourage a prioritized investigation. Use of NSAID, PPI, and ASA may affect the diagnostic accuracy of FC for IBD and OGID.
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Collaborators (12)
Per Stal
Karolinska Institutet
Mattias Ekstedt
Linköping University
Henrik Hjortswang
-
Örjan Dahlström
Linköpings universitet Tekniska högskolan
Anna Oksanen
Karolinska Institutet
Martin Henriksson
Linköping University
Johan Rönnelid
Uppsala University
Fredrik Iredahl
Linköping University
Magnus Holmer
Karolinska University Hospital
Stefano Romeo
-
Catarina Lindqvist
Karolinska University Hospital
Karin Rådholm
Linköping University
Make your next move.
Prepare your application
Review drafts before you send them.